Trajan Wealth’s Matinas BioPharma MTNB Stock Holding History

Trajan Wealth’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-200	Closed	-$1.58K	–	186
2024 Q2	$1.58K	Sell	200 -174	-47%	-$1.58K	﹤0.01%	164
2024 Q1	$5.07K	Buy	+374	New	+$4.44K	﹤0.01%	183

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return

Trajan Wealth's MTNB Position: Q3 2024 in Review

Trajan Wealth sold out of Matinas BioPharma (MTNB) in Q3 2024, closing a stake of 200 shares — an estimated $1.58K sold.

Trajan Wealth first reported a position in MTNB in Q1 2024 and held it in 2 quarters. The position peaked at $5.07K in Q1 2024. 18 funds tracked by Wall St. Rank hold MTNB as of Q3 2024.

Trajan Wealth reported no remaining Matinas BioPharma position as of Q3 2024 after selling out during the quarter.
Trajan Wealth sold 200 Matinas BioPharma shares in Q3 2024, an estimated $1.58K.
Trajan Wealth first reported a position in Matinas BioPharma in Q1 2024 and held it in 2 quarters.
Trajan Wealth's Matinas BioPharma position peaked at $5.07K in Q1 2024.
18 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2024.

Based on Trajan Wealth's 13F filing for Q3 2024, filed 25 Oct 2024.